Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07131631 · ClinicalTrials.gov registry record
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
A clinical trial of Functional Mitral Regurgitation and Heart Failure and Reduced Ejection Fraction, sponsored by Minneapolis Heart Institute Foundation.
- Recruiting
- Registry status
- 125
- Enrollment target
- 6
- Study locations
NCT07131631 is a study of Functional Mitral Regurgitation and Heart Failure and Reduced Ejection Fraction that is actively recruiting participants, run by Minneapolis Heart Institute Foundation. The registered enrollment target is 125 participants, below the 406-participant average among 5 other Functional Mitral Regurgitation trials with a reported enrollment target (69% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT07131631, a study of Functional Mitral Regurgitation and Heart Failure and Reduced Ejection Fraction, is actively recruiting participants, sponsored by Minneapolis Heart Institute Foundation.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up. Enrollment will occur at up to eight centers.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Cardiac MRI
Study Locations (6)
Ohio
- The Christ Hospital Health Network - Cincinnati
- Cleveland Clinic - Cleveland
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
North Carolina
- Sanger Heart and Vascular Institute - Charlotte
Virginia
- Inova Fairfax Medical Campus - Falls Church
Other
- IRCCS Ospedale San Raffaele - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2027-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07131631
The ClinicalTrials.gov registry entry for NCT07131631 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 406-participant average among 5 other Functional Mitral Regurgitation trials with a reported enrollment target (69% lower). The listed sponsor is Minneapolis Heart Institute Foundation, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Functional Mitral Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Cardiac MRI is the first listed.
NCT07131631 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Ohio, Minnesota, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07131631 about?
NCT07131631 is a clinical study titled "Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance". This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up....
What is the current status of trial NCT07131631?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2022-03-03. Estimated completion is 2027-07.
What conditions does trial NCT07131631 study?
This clinical trial studies the following conditions: Functional Mitral Regurgitation, Heart Failure and Reduced Ejection Fraction.
What interventions are being tested in trial NCT07131631?
The interventions under investigation include: Cardiac MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07131631?
This trial is sponsored by Minneapolis Heart Institute Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07131631 being conducted?
This trial has 6 study locations across Minnesota, North Carolina, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Functional Mitral Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR
RECRUITING · NA
-
Phenotypic Classification of FMR With CMR
RECRUITING
-
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
ACTIVE NOT RECRUITING · NA
-
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
ACTIVE NOT RECRUITING · NA
-
NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Functional Mitral Regurgitation
All registered trials for this condition
Heart Failure and Reduced Ejection Fraction
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.